Conversions of tricyclic antidepressants and antipsychotics with selected P450s from sorangium cellulosum so ce56

Drug Metabolism and Disposition

Volumn 43, Issue 3, 2015, Pages 392-399

  Litzenburger, Martin ^a   Kern, Fredy ^a   Khatri, Yogan ^a   Bernhardt, Rita ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; CYP109C1 PROTEIN; CYP109C2 PROTEIN; CYP109D1 PROTEIN; CYP260A1 PROTEIN; CYP260B1 PROTEIN; CYP264A1 PROTEIN; CYP264B1 PROTEIN; CYP266A1 PROTEIN; CYP267A1 PROTEIN; CYP267B1 PROTEIN; CYTOCHROME P450; DRUG METABOLITE; IMINODIBENZYL; IMIPRAMINE; NEUROLEPTIC AGENT; PHENOTHIAZINE; PROMETHAZINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSFORMATION; IN VITRO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SCALE UP; SORANGIUM CELLULOSUM; STRUCTURE ANALYSIS; SULFOXIDATION; BIOTRANSFORMATION; ESCHERICHIA COLI; METABOLISM; MYXOCOCCALES; PHYSIOLOGY;

ESCHERICHIA COLI; POLYANGIUM CELLULOSUM;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; ESCHERICHIA COLI; MYXOCOCCALES;

EID: 84921729873     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.061937     Document Type: Article

References (60)

1. Asha S and Vidyavathi M (2009) Cunninghamella-a microbial model for drug metabolism studies-a review. Biotechnol Adv 27:16-29.
2. Bernhardt R (2006) Cytochromes P450 as versatile biocatalysts. J Biotechnol 124:128-145.
3. Bernhardt R and Urlacher VB (2014) Cytochromes P450 as promising catalysts for bio-technological application: chances and limitations. Appl Microbiol Biotechnol 98:6185-6203.
4. Caswell JM, O'Neill M, Taylor SJ, and Moody TS (2013) Engineering and application of P450 monooxygenases in pharmaceutical and metabolite synthesis. Curr Opin Chem Biol 17: 271-275.
5. Crespi CL, Langenbach R, and Penman BW (1993) Human cell lines, derived from AHH-1 TK+/-human lymphoblasts, genetically engineered for expression of cytochromes P450. Toxicology 82:89-104.
6. Cunningham Owens, D. G. A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. 2nd ed. Cambridge: Cambridge University Press, 2014. Cambridge Books Online http://dx.doi.org/10.1017/CBO9781139149112.
7. Daniel WA, Syrek M, Haduch A, and Wójcikowski J (2000) Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants. Br J Pharmacol 131: 287-295.
8. Demain AL (1999) Pharmaceutically active secondary metabolites of microorganisms. Appl Microbiol Biotechnol 52:455-463.
9. Döhmer J (2001) [Modern drug development by molecular-and cell-biological methods]. ALTEX 18:9-12.
10. Dragan CA, Peters FT, Bour P, Schwaninger AE, Schaan SM, Neunzig I, Widjaja M, Zapp J, Kraemer T, and Maurer HH, et al. (2011) Convenient gram-scale metabolite synthesis by engineered fission yeast strains expressing functional human P450 systems. Appl Biochem Biotechnol 163:965-980.
11. European Medicines Agency (2009) ICH Guidance M3(R2) on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorisation for Pharmaceuticals, European Medicines Agency, London.
12. Food and Drug Administration (2008) Guidance for Industry: Safety Testing of Drug Metabolites, U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD.
13. Frederick CB and Obach RS (2010) Metabolites in safety testing: "MIST" for the clinical pharmacologist. Clin Pharmacol Ther 87:345-350.
14. Frigerio A, Belvedere G, De Nadai F, Fanelli R, Pantarotto C, Riva E, and Morselli PL (1972) A method for the determination of imipramine in human plasma by gas-liquid chromatography-mass fragmentography. J Chromatogr A 74:201-208.
15. Geier M, Braun A, Emmerstorfer A, Pichler H, and Glieder A (2012) Production of human cytochrome P450 2D6 drug metabolites with recombinant microbes-a comparative study. Biotechnol J 7:1346-1358.
16. Gillam EM (2008) Engineering cytochrome p450 enzymes. Chem Res Toxicol 21:220-231.
17. Girhard M, Klaus T, Khatri Y, Bernhardt R, and Urlacher VB (2010) Characterization of the versatile monooxygenase CYP109B1 from Bacillus subtilis. Appl Microbiol Biotechnol 87: 595-607.
18. Haglund J, Halldin MM, Brunnström A, Eklund G, Kautiainen A, Sandholm A, and Iverson SL (2014) Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phase. Chem Res Toxicol 27:601-610.
19. Handa K, Nakagome I, Yamaotsu N, Gouda H, and Hirono S (2014) In silico study on the inhibitory interaction of drugs with wild-type CYP2D6.1 and the natural variant CYP2D6.17. Drug Metab Pharmacokinet 29:52-60.
20. Hannemann F, Bichet A, Ewen KM, and Bernhardt R (2007) Cytochrome P450 systems-biological variations of electron transport chains. Biochim Biophys Acta 1770:330-344.
21. Julsing MK, Cornelissen S, Bühler B, and Schmid A (2008) Heme-iron oxygenases: powerful industrial biocatalysts? Curr Opin Chem Biol 12:177-186.
22. Jung ST, Lauchli R, and Arnold FH (2011) Cytochrome P450: taming a wild type enzyme. Curr Opin Biotechnol 22:809-817.
23. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, and Levy RH (1994) Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation. Biochem Pharmacol 47:1969-1979.
24. Khatri Y, Girhard M, Romankiewicz A, Ringle M, Hannemann F, Urlacher VB, Hutter MC, and Bernhardt R (2010a) Regioselective hydroxylation of norisoprenoids by CYP109D1 from Sorangium cellulosum So ce56. Appl Microbiol Biotechnol 88:485-495.
25. Khatri Y, Hannemann F, Ewen KM, Pistorius D, Perlova O, Kagawa N, Brachmann AO, Müller R, and Bernhardt R (2010b) The CYPome of Sorangium cellulosum So ce56 and identification of CYP109D1 as a new fatty acid hydroxylase. Chem Biol 17:1295-1305.
26. Khatri Y, Hannemann F, Girhard M, Kappl R, Hutter M, Urlacher VB, and Bernhardt R (2014) A natural heme-signature variant of CYP267A1 from Sorangium cellulosum So ce56 executes diverse co-hydroxylation. FEBS J 10:13104.
27. Khatri Y, Hannemann F, Girhard M, Kappl R, Même A, Ringle M, Janocha S, Leize-Wagner E, Urlacher VB, and Bernhardt R (2013) Novel family members of CYP109 from Sorangium cellulosum So ce56 exhibit characteristic biochemical and biophysical properties. Biotechnol Appl Biochem 60:18-29.
28. Koeller KM and Wong C-H (2001) Enzymes for chemical synthesis. Nature 409:232-240.
29. Ly TT, Khatri Y, Zapp J, Hutter MC, and Bernhardt R (2012) CYP264B1 from Sorangium cellulosum So ce56: a fascinating norisoprenoid and sesquiterpene hydroxylase. Appl Microbiol Biotechnol 95:123-133.
30. Murphy CD (2015) Drug metabolism in microorganisms. Biotechnol Lett 37:19-28.
31. Murray M (2006) Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 58:871-885.
32. Nakamura K, Yokoi T, Inoue K, Shimada N, Ohashi N, Kume T, and Kamataki T (1996) CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics 6:449-457.
33. Nelson DR (2011) Progress in tracing the evolutionary paths of cytochrome P450. Biochim Biophys Acta 1814:14-18.
34. Nielsen KK, Flinois JP, Beaune P, and Brøsen K (1996) The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 277:1659-1664.
35. Patel RN (2002) Microbial/enzymatic synthesis of chiral intermediates for pharmaceuticals. Enzyme Microb Technol 31:804-826.
36. Pearce RE, Vakkalagadda GR, and Leeder JS (2002) Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2-and 3-hydroxylated metabolites. Drug Metab Dispos 30:1170-1179.
37. Prox A and Breyer-Pfaff U (1987) Amitriptyline metabolites in human urine. Identification of phenols, dihydrodiols, glycols, and ketones. Drug Metab Dispos 15:890-896.
38. Ringle M, Khatri Y, Zapp J, Hannemann F, and Bernhardt R (2013) Application of a new versatile electron transfer system for cytochrome P450-based Escherichia coli whole-cell bioconversions. Appl Microbiol Biotechnol 97:7741-7754.
39. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, Lewis CJ, Tennant MG, Modi S, and Eggleston DS, et al. (2006) Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614-7622.
40. Sagara Y, Wada A, Takata Y, Waterman MR, Sekimizu K, and Horiuchi T (1993) Direct expression of adrenodoxin reductase in Escherichia coli and the functional characterization. Biol Pharm Bull 16:627-630.
41. Sakaki T (2012) Practical application of cytochrome P450. Biol Pharm Bull 35:844-849.
42. Schifrin A, Ly TT, Günnewich N, Zapp J, Thiel V, Schulz S, Hannemann F, Khatri Y, and Bernhardt R (2015) Characterization of the gene cluster CYP264B1-geoA from Sorangium cellulosum So ce56: Biosynthesis of (1)-eremophilene and its hydroxylation. ChemBioChem, 16:337-344
43. Schneiker S, Perlova O, Kaiser O, Gerth K, Alici A, Altmeyer MO, Bartels D, Bekel T, Beyer S, and Bode E, et al. (2007) Complete genome sequence of the myxobacterium Sorangium cellulosum. Nat Biotechnol 25:1281-1289.
44. Shen WW (1999) A history of antipsychotic drug development. Compr Psychiatry 40:407-414.
45. Shimkets L, Dworkin M, and Reichenbach H (2006) The myxobacteria, in The Prokaryotes (Dworkin M, Falkow S, Rosenberg E, Schleifer KH, and Stackebrandt E eds) pp 31-115, Springer, New York.
46. Singh JK, Solanki A, and Shirsath VS (2012) Comparative in-vitro intrinsic clearance of imip-ramine in multiple species liver microsomes: human, rat, mouse and dog. Drug Metab Toxicol 3:1000126.
47. Sono M, Roach MP, Coulter ED, and Dawson JH (1996) Heme-containing oxygenases. Chem Rev 96:2841-2888.
48. Tanaka E and Hisawa S (1999) Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther 24:7-16.
49. Uhlmann H, Kraft R, and Bernhardt R (1994) C-terminal region of adrenodoxin affects its structural integrity and determines differences in its electron transfer function to cytochrome P-450. J Biol Chem 269:22557-22564.
50. Underberg WJ (1978) Oxidative degradation of pharmaceutically important phenothiazines I: Isolation and identification of oxidation products of promethazine. J Pharm Sci 67:1128-1131.
51. Urlacher VB and Girhard M (2012) Cytochrome P450 monooxygenases: an update on perspectives for synthetic application. Trends Biotechnol 30:26-36.
52. Urlacher VB, Lutz-Wahl S, and Schmid RD (2004) Microbial P450 enzymes in biotechnology. Appl Microbiol Biotechnol 64:317-325.
53. Venkatakrishnan K, Schmider J, Harmatz JS, Ehrenberg BL, von Moltke LL, Graf JA, Mertzanis P, Corbett KE, Rodriguez MC, and Shader RI, et al. (2001) Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol 41: 1043-1054.
54. Weissman KJ and Müller R (2010) Myxobacterial secondary metabolites: bioactivities and modes-of-action. Nat Prod Rep 27:1276-1295.
55. Whitehouse CJC, Bell SG, and Wong L-L (2012) P450(BM3) (CYP102A1): connecting the dots. Chem Soc Rev 41:1218-1260.
56. Wójcikowski J, Boksa J, and Daniel WA (2010) Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver-A comparison with other phenothiazines. Biochem Pharmacol 80:1252-1259.
57. Yokono A, Morita S, Someya T, Hirokane G, Okawa M, and Shimoda K (2001) The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. J Clin Psychopharmacol 21:549-555.
58. Yun CH, Kim KH, Kim DH, Jung HC, and Pan JG (2007) The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol 25:289-298.
59. Zanger UM and Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138: 103-141.
60. Ziegler DM (1993) Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 33:179-199.